Are all aromatase inhibitors the same? A review of the current evidence
- 31 December 2004
- journal article
- review article
- Published by Elsevier in The Breast
- Vol. 13 (1) , 10-18
- https://doi.org/10.1016/j.breast.2004.09.003
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Aromatase Inhibitors for Breast Cancer in Postmenopausal WomenThe Oncologist, 2004
- The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized ratsBone, 2004
- An open randomised trial of second-line endocrine therapy in advanced breast cancerEuropean Journal Of Cancer, 2003
- The role of aromatase inhibitors in the treatment of metastatic breast cancerSeminars in Oncology, 2003
- Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2003
- Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over StudyJournal of Clinical Oncology, 2002
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter studyAnnals of Oncology, 2001
- Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized TrialJournal of Clinical Oncology, 2001
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998